Codiak BioSciences has filed for Chapter 11 bankruptcy, spelling an end to the employment of most executives, including founder Doug Williams, as the biotech says it “expects to consummate a sale.”

The eight-year journey at Codiak is nearing an end with Williams; CFO Linda Bain; medical chief David Mauro; scientific head Sriram Sathyanarayanan; legal and compliance chief Yalonda Howze; and SVP of HR Nicole Barna all packing up their bags in the first few days of April. Chief technology officer Konstantin Konstantinov will stay.

DC District Court Judge Christopher Cooper today granted Vanda Pharma’s request to require the FDA to disclose more info on the complete response letter for its sleep disorder drug Hetlioz.

The melatonin receptor agonist is approved by the FDA to treat non-24-hour sleep-wake disorder, a circadian rhythm disorder. But in 2018 Vanda filed a supplemental application to market Hetlioz as a treatment for jet lag, which the FDA rejected in August 2019, with few details on what Vanda needed to correct course, according to the company.

In May, the Ferring Research Institute in San Diego will let all 89 of its employees go.

Led by SVP of global drug discovery and external innovation Araz Raoof, the institute works on small molecule and peptide drug discovery, as well as machine learning and artificial intelligence work to find new drug targets, according to Ferring’s website.

The Swiss biopharma notified its employees last week, per a California WARN notice, which was first reported by Fierce Biotech. Ferring refers to the center as its “global research arm and ideas incubator.” The drug developer’s pipeline includes work across reproductive medicine and maternal health, gastroenterology, urology and url-oncology.

Jim Mullen is lending his years of biotech CEO experience — from Biogen, Patheon and Editas — to the private equity firm Advent International.

Advent managing partner John Maldonado said Mullen will help his team expand their reach to pharmaceutical and pharma services companies “across contract manufacturing, commercialization, and research.”

“Jim’s work at Editas and Thermo Fisher have put him at the forefront of the cell and gene therapy revolution,” Carmine Petrone, managing director at Advent, added in a statement. “We are excited to partner with Jim as we continue to look for transformative companies that are enabling the development, manufacture and commercialization of these advanced therapies.”